Clinical Trials Using Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Multi-peptide CMV-Modified Vaccinia Ankara Vaccine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

    This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, in people whose immune systems are lowered (such as those undergoing stem cell transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce immunity (the ability to recognize and respond to an infection) and reduce the risk of developing complications related to CMV infection.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients with Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

    This phase I / II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants with Blood Cancer Undergoing Donor Stem Cell Transplant

    This phase I trial studies the side effects of multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing donor stem cell transplant. Giving a vaccine to the donors may boost the recipient's immunity to this virus and reduce the chance of CMV disease after transplant.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California